.gif)
MOST NOTEWORTHY: Beckman Coulter, BT Group and Micromet were today's noteworthy initiations:
- Oppenheimer believes Beckman Coulter (NYSE:BEC) is well-positioned to leverage its broad installed base in the clinical lab market to increase sales of its consumable and a new molecular diagnostics instrument expected in 2010. The firm initiated shares with an Outperform rating and $80 target.
- Societe Generale expects BT Group's (NYSE:BT) domestic revenues to deteriorate as line erosion accelerates; shares were assumed with a Sell rating.
- Roth Capital started Micromet (NASDAQ:MITI) with a Buy rating and $3 target. The firm expects the company's proprietary 'BiTE' antibody platform to gain validation as its lead candidate MT103 starts accumulating clinical data in multiple hematology indications.
OTHER INITIATIONS:
- Yahoo! (NASDAQ:YHOO) was initiated with a Neutral rating at Merrill.
- Piper resumed coverage of Alexion Pharma (NASDAQ:ALXN) with a Buy rating and $88 target.
- MedAssets (NASDAQ:MDAS) was started at Jefferies with a Buy rating and $25 target.
Cramer on BloggingStocks: Not much time left for downside 
Foreclosures fall, but are still higher than a year ago
HP's deal for 3Com: A missile launch at Cisco?
